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Abstract 1 
In this study, by phylogenetic-analysis, we identified an epidemiological-cluster involving 8 2 
individuals diagnosed for acute HBV-infection related to unprotected sexual-intercourses in a 3 
restricted area of Central Italy (time-period: 2011-2014). Notably, these patients (6/8 Italians) were 4 
infected by sub-genotype F1b, not commonly found in Western-Countries. Ultra-deep 5 
pyrosequencing confirms a superimposable composition of HBV-quasispecies in these patients. 6 
Despite the availability of effective vaccination, this study highlights the importance not to 7 
underestimate the risk of HBV-infection, to continue to set-up surveillance programs for HBV-8 
infection, and to investigate the pathogenetic potential of these atypical genotypes. 9 
 10 
 11 
 12 
Keywords: HBV, Genotype, Vaccine, Acute infection, Epidemiological-cluster.  13 
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Background 1 
Ten HBV-genotypes (A-H plus tentative genotypes I and J) and sub-genotypes were so far 2 
identified based on intergroup divergence of 8% or 4% in complete HBV-genome, respectively [1]. 3 
Among them, genotype F was divided into four sub-genotypes (HBV/F1-F4). HBV/F1 is found in 4 
Central America (HBV/F1a), Alaska and South America (HBV/F1b). HBV/F3 is found in Central 5 
America and in northern South America, whereas HBV/F2a, HBV/F2b and HBV/F4 are found in 6 
South America [2]. 7 
In this study, we described a local epidemiological-cluster of acute HBV-infection, sexually 8 
transmitted in a short time period, involving 8 individuals infected with sub-genotype F1b.  9 
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Methods 1 
Protocols used for population and ultra-deep HBV-sequencing, and for phylogenetic analysis were 2 
extensively reported in Supplementary Materials (SM_I-III). 3 
Results  4 
Between November 2011 and May 2014, 8 individuals (7 females and 1 male) were diagnosed for 5 
acute HBV-infection in two Hospitals of Abruzzo region in Central Italy (defined as A-H in Fig_1, 6 
Table_1). The definition of acute HBV-infection was based on: HBsAg and IgM anti-HBc 7 
positivity, and ALT levels >10 times the normal value. All patients had a compatible clinical history 8 
for acute HBV-infection.  9 
All individuals referred unprotected sexual intercourses within weeks before the appearance of 10 
symptoms. Specific risk factors for blood-related transmission were excluded (no tattoos, no 11 
transfusion of blood or blood derivatives, no drug use, no unsafe healthcare-related injection 12 
practices). No patients worked in a health care setting or live with HBsAg-positive individuals.  13 
Six individuals (not-vaccinated for HBV) were Italian (age from 37 to 59 years), and two were from 14 
Philippine and Argentina (age of 26 and 44 years, respectively) (Table_1). The 7 women (patients: 15 
B-H) spontaneously resolved HBV-infection (HBsAg-negative, anti-HBc-positive +/-anti-HBs). 16 
The only man (patient_A) showing a HBsAg-persistence for 6 months, resolved the infection as 17 
consequence of anti-HBV treatment.  18 
For diagnostic purposes, a genotypic test based on the population-based sequencing of HBV 19 
Reverse-Transcriptase (RT)/HBsAg (SM_I), was performed at the University Hospital “Tor 20 
Vergata”, Rome, Italy. This test revealed no drug-resistance RT-mutations, and some amino acids 21 
(wild-type in F1b genotype) at specific HBsAg-positions (L110_T114_K122_L127_F134_S140) 22 
known to affect HBsAg-recognition by antibodies (http://hbv.bioinf.mpi-inf.mpg.de/index.php).   23 
Phylogenetic-analysis by NJ method (SM_II) showed that the RT-sequences from the 8 individuals 24 
belonged to HBV F1b subgenotype, and formed a well-defined cluster (bootstrap-value >90%) 25 
(Fig_S1). Once HBV-genotype was assigned, the statistical robustness of cluster was confirmed by 26 
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ML tree (SM_II), containing only HBV/F1b RT-sequences and HBV/F1a RT-sequences used as 1 
outgroup (Fig_1A). Again, RT-sequences from the 8 individuals formed a cluster distinct from the 2 
other 70 F1b RT-sequences included in the analysis (bootstrap >85%) (Fig_1A). 3 
This cluster was confirmed also by analyzing concatenated HBV/F1b BCP/Pre-Core/Core/RT-4 
sequences (bootstrap >85%) (Fig_1B). 5 
Finally, the mean genetic distance in both RT and BCP/pre-Core/Core-sequences involved in the 6 
cluster was extremely low (RT:0.00006, standard error [SE]:±0.00001; BCP/pre-Core/Core:0.00001 7 
[SE:±0.0000001]), confirming a high homology among sequences. 8 
Furthermore, the composition of HBV-quasispecies in the 8 individuals involved in the cluster was 9 
investigated by UDPS, performed on RT/HBsAg and BCP/Pre-Core/Core regions (SM_III).  10 
The patterns of mutations detected in these genomic regions, with an intra-patient prevalence 11 
ranging from 10 to 100%, were superimposable in all the 8 individuals (Table_S1).   12 
Only in patient H, additional mutations were detected in BCP, all with prevalence of 100% 13 
(Table_S1). 14 
Conversely, the patterns of mutations detected in RT/HBsAg and BCP/Precore/Core, with an intra-15 
patient prevalence <10%, varied among the patients (Table_S1), suggesting a genetic diversification 16 
only at the level of minority species.  17 
Discussion 18 
This study provides molecular evidence of a local epidemiological-cluster involving 8 individuals, 19 
diagnosed for acute HBV-infection related to unprotected sexual intercourses in a restricted area of 20 
Central Italy (all resident in two cities no more than 115 Km apart) in a short period of time.  21 
Previous European studies reported epidemiological-clusters mainly in the setting of nosocomial 22 
infections [3, 4]. To our knowledge, this is the first study showing an epidemiological-cluster not 23 
sustained by an iatrogenic route of infection.  24 
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We emphasize that this is  an epidemiological-cluster and not a transmission-chain. Thus, we cannot 1 
exclude the involvement of other individuals (not-identified) contributing to HBV/F1b-2 
transmission.   3 
In the cluster identified, the 8 individuals were not-vaccinated: 6  Italians and 2 from Countries 4 
where the vaccination coverage is middle/low. In Italy, the nationwide HBV-vaccination program 5 
has targeted all infants born since 1992, and adolescents born between 1980-1991. Thus, there is a 6 
reservoir of Italian population (sexually-active) born before 1980, susceptible to HBV-infection. 7 
This suggests the importance to encourage a larger portion of adult individuals to HBV-vaccination 8 
and to offer HBV-vaccination to foreign individuals negative for HBV-infection.  9 
This epidemiological-cluster was sustained by sub-genotype F1b, not commonly found in Europe. 10 
This raises the issue on the circulation of non-D and non-A genotypes progressively increasing in 11 
Western-Countries. Epidemiological models have shown that, within next decades, HBV-12 
epidemiology will be completely modified by waves of immigration, affecting the local prevalence 13 
of HBV-infection, routes of transmission, and impacting prophylactic, diagnostic and therapeutic 14 
measures [5, 6]. The imported HBV-infections can be also transmitted to native population (as 15 
described in this cluster), further contributing to the spread of atypical genotypes. 16 
Furthermore, HBV-genotypes are known to profoundly affect the natural history of HBV-infection. 17 
In particular, it is known the faster progression of genotype C and E to liver-cancer [7]. This was 18 
recently described also for genotype F [2]. Thus, the increased prevalence of these genotypes in 19 
Western-Countries may have implications for the burden and clinical management of liver-related 20 
morbidity and mortality. 21 
In the epidemiological-cluster identified, all individuals resolved acute HBV-infection. It is known 22 
that the resolution of acute HBV-infection does not imply HBV eradication, but its persistence in an 23 
occult form in the vast majority of patients [8-10]. Occult HBV-infection is recognized as a co-24 
factor promoting liver-cancer [11, 12], and can reactivate spontaneously or under immune-25 
suppression conditions. These observations suggest to set-up interventions aimed at promoting 26 
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screening and (when necessary) treatment at the migrant groups coming from Countries with high 1 
HBV-prevalence. 2 
In conclusions, despite the availability of effective vaccination, this study highlights the need not to 3 
underestimate the risk of HBV-infection, to continue to set-up surveillance programs of HBV-4 
infection, and to investigate the pathogenetic potential of these atypical genotypes. 5 
 6 
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Legend to Figures  1 
Figure_1. A) Maximum likelihood phylogenetic tree was constructed by using HBV F1b RT-2 
sequences from: 70 isolates downloaded from GenBank, 8 individuals involved in the cluster, and 2 3 
individuals collected from routine laboratory testing at the University Hospital “Tor Vergata” 4 
(identified with arabic numbers). Two HBV F1a RT-sequences were used as outgroup. B) 5 
Maximum likelihood phylogenetic tree was constructed by using concatenated HBV F1b 6 
BCP/preCore/Core/RT-sequences from: 58 isolates downloaded from GenBank, and 5 individuals 7 
involved in the cluster. Two HBV F1a BCP/preCore/Core/RT-sequences were used as outgroup. 8 
Branch lengths were estimated with the best fitting nucleotide substitution model (GTR+G+I) 9 
according to a hierarchical likelihood ratio test. The bar at the bottom indicating 0.001 nucleotide 10 
substitution per site. The asterisks (*) along a branch represent bootstrap support >85%. The 11 
clusters involving the 8 HBV F1b RT-sequences and the 5 concatenated RTS/BCP/preCore/Core-12 
sequences are in the grey box. 13 
Figure_S1: Neighbour joining phylogenetic tree constructed on the polymerase gene sequences of 14 
659 isolates and additional 155 HBV F genotypes references. The bar at the bottom of the tree 15 
indicates 0.01 nucleotide substitution per site. Isolates of genotype F1b are shown in red, and 16 
isolates of genotype F1a are in blue. The cluster involving the 8 HBV F1b sequences is in the grey 17 
box. Bootstrap values ≥80% were showed.  18 
 19 
 20 
 21 
 22 
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Table_1. Characteristics of patients. 
 
a
 This date is referred to the blood sample withdrawal for genotypic testing 
b
 Values are those observed at the time of genotypic testing 
c
 For this patient only qualitative HBsAg was available  
n.a. Not available data 
 
A B C D E G F H
SEX M F F F F F F F
NATIONALITY ITALIAN ITALIAN PHILIPPINE ITALIAN ITALIAN ITALIAN ITALIAN ARGENTINIAN
AGE (YEARS) 59 37 26 40 43 58 39 44
DATE OF BLOOD SAMPLE COLLECTION
a
March 2012 February 2014 February 2014 November 2013 November 2013 September 2013 September 2013 May 2014
SERUM HBV DNA (IU/ml)
b
>170,000,000 462 6,490 5,233 54 346,176 1578 44,346
AST
b
55 341 1,510 1,776 565 1,379 61 1,421
ALT
b
157 1,305 2,227 2,663 2,324 2,237 122 1,865
HBSAg (IU/ml)
b
115,261 7,765 10,292 153 1,360 23 1,481 positive 
c
ANTI HBS
b
- - - - - - - -
HBeAg
b
+ + + + - + - n.a.
ANTI Hbe
b
- + - + + - + n.a.
HBcAg IgG/IgM
b
+ + + + + + + +
PATIENTS
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A
B
Figure 1
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F1a
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Supplementary Methods I 1 
Population-based sequencing of HBV Reverse Transcriptase, HBsAg, Basal Core Promoter/Pre-2 
Core/Core. 3 
The population-based sequencing of HBV Reverse-Transcriptase (RT), Basal Core Promoter 4 
[BCP]/Pre-Core/Core was performed on plasma samples, following home-made protocols as 5 
described below [6,7]. Due to the overlapping between the RT and HBsAg genes, RT-sequences 6 
were also used to analyze the HBsAg region. RT/HBsAg population-based sequencing was 7 
available for 8/8 patients, and BCP/Pre-Core/Core population-based sequencing for 5/8 patients. 8 
Mutations were defined as amino acid (aa) variation from the HBV F1b reference sequence. 9 
Details of the protocols for the Population-based sequencing of HBV Reverse Transcriptase, 10 
HBsAg, Basal Core Promoter/Pre-Core/Core were reported below. 11 
HBV DNA Extraction. 12 
HBV-DNA was extracted using a commercially available kit (QIAmp DNA blood mini-kit, Qiagen 13 
Inc., USA). 14 
Protocol for population-based sequencing of HBV Reverse Transcriptase/HBsAg. 15 
Extracted HBV DNA was amplified with Amplitaq-Gold polymerase using the following primer 16 
pairs: F1-5’GGTCACCATATTCTTGGGAA and R1-5’GTGGGGGTTGCGTCAGCAAA. 17 
Polimerase chain reaction (PCR) conditions were: one cycle at 93 °C for 12 min, 40 cycles (94 °C 18 
50 s, 57 °C 50 s, 72 °C 1 min and 30 s), and a final cycle at 72 °C for 10 min. For samples with 19 
serum low HBV-DNA, 2 additional heminested-PCR were performed, starting from the same first 20 
amplicon: eminested_1 used the following primer pairs (F1-5’GGTCACCATATTCTTGGGAA 21 
and R2-GAGGACAAACGGGCAACATACCTT and eminested-2 used F2-22 
GTTGACAAGAATCCTCACAATA and R1-5’GTGGGGGTTGCGTCAGCAAA. Both 23 
eminested-PCRs conditions were: one cycle at 93 °C for 12 min, 35 cycles (94 °C 50 s, 56 °C 50 s, 24 
72 °C 1 min), and a final cycle at 72 °C for 10 min. PCR-products were purified and sequenced by 25 
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using eight different overlapping sequence-specific primers, a BigDye terminator v. 3.1 cycle 1 
sequencing kit (Applied-Biosystems FosterCity, CA) and an automated sequencer (Genetic 2 
Analyzer 3130XL). The sequences were analyzed using SeqScape-v.2.5 software. The quality 3 
endpoint for each individual gene was ensured by a coverage of the S gene sequence by at least two 4 
segments. Sequences having a mixture of wild-type and mutant residues at single positions were 5 
considered to have the mutant(s) at that position. 6 
Protocol for population-based sequencing of HBV Basal Core Promoter, Pre-Core, Core 7 
region. 8 
Extracted HBV DNA was amplified with Amplitaq-Gold polymerase using the following primer 9 
pairs: F1-5’ CCCAAGGTCTTACATAAGAGGACT and R1-5’ 10 
CCACCTTATGAGTCCAAGGAA. PCR and Nested-PCR conditions were: one cycle at 94 °C for 11 
10 min, 40 cycles (94 °C 30 s, 54 °C 30 s, 72 °C 1 min), and a final cycle at 72 °C for 10 min. For 12 
samples with serum low HBV-DNA, one additional nested-PCR was performed, used the following 13 
primer pairs (F2-5’ TTAAAGACTGGGAGGAGTTGGG and R1-5’ 14 
CCACCTTATGAGTCCAAGGAA). 15 
PCR-products were purified and sequenced by using six different overlapping sequence-specific 16 
primers, a BigDye terminator v. 3.1 cycle sequencing kit (Applied-Biosystems FosterCity, CA) and 17 
an automated sequencer (Genetic Analyzer 3130XL). The sequences were analyzed using 18 
SeqScape-v.2.5 software. The quality endpoint for each individual gene was ensured by a coverage 19 
of the S gene sequence by at least two segments. Sequences having a mixture of wild-type and 20 
mutant residues at single positions were considered to have the mutant(s) at that position. 21 
The list of drug resistance mutations in RT and immune escape mutations in HBsAg was retrieved 22 
at the following website http://hbv.bioinf.mpi-inf.mpg.de/index.php updated on October 2013. 23 
Supplementary Methods II 24 
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Phylogenetic analysis. HBV RT-sequences, obtained by population-based sequencing, were 1 
aligned using CLUSTAL X software [8], and manually edited with the Bioedit program [9]. 2 
To define the sequence inter-relationships among the 8 HBV isolates and their HBV sub-genotype, 3 
a neighbor joining (NJ) tree [10] was constructed using a first dataset containing HBV RT reference 4 
sequences of the major HBV-genotypes, and 659 full-length RT-sequences (1,342bp) obtained from 5 
routine laboratory testing at the Virology Unit Hospital “Tor Vergata”, in Rome, Italy. The dataset 6 
of 659 RT-sequences included the RT-sequences of the 8 patients involved in the cluster. The 7 
reliability of the branching orders was assessed by bootstrap analysis of 1000 replicates. HBV 8 
reference sequences were retrieved from GenBank (please, cite SM_III for the accession numbers). 9 
The robustness of the epidemiological cluster was further tested using the maximum likelihood 10 
(ML) method. This was inferred by the PhyML program (http://www.atgc-montpellier.fr/phyml/) 11 
using the GTR+I+Γ nucleotide substitution model. The simplest model that adequately fitted the 12 
sequence data was selected according to the Akaike Information Criterion (AIC) [11] included in 13 
the MEGA package (version 6.0). Robustness of the phylogenetic clades was evaluated by 14 
bootstrap analysis (1,000 replicates). For the maximum likelihood phylogenetic tree, the dataset 15 
included 80 full-length HBV F1b RT-sequences from: 70 isolates downloaded from GenBank, the 8 16 
individuals involved in the cluster, and 2 individuals collected from routine laboratory testing at the 17 
University Hospital “Tor Vergata”. Two HBV F1a RT-sequences were used as outgroup.  18 
For 5 out of 8 patients, population-based BCP/Pre-Core/Core-sequences were available. These 19 
BCP/Pre-Core/Core sequences were concatenated to the corresponding RT-sequences, and used to 20 
infer the phylogenetic tree by ML method (bootstrap analysis based on 1,000 replicates). In this ML 21 
phylogenetic tree, additional 58 F1b and 2 F1a BCP/Pre-Core/Core/RT-sequences (downloaded 22 
from GenBank) were included. 23 
The accession number of the sequences downloaded from GenBank are the following: JX849628.1 24 
(Genotype-A); AY128092.1 (Genotype-A); AB033554.1 (Genotype-B); AB014381.1 (Genotype-25 
C); V01460.1 (Genotype D3), AM494706.1 (Genotype-E); AF405706.1 (Genotype-G); 26 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
4 
 
AY090454.1 (Genotype-H); HE974366 (Genotype-F2b), HE974368 (Genotype-F4), CS409748 1 
(Genotype-F3), CS388978 (Genotype-F3), AB365453 (Genotype-F4), AF223965 (Genotype-F4), 2 
AY311369 (Genotype-F2a), DQ899142 (Genotype-F2a), DQ899144 (Genotype-F2b), AB036920 3 
(Genotype-F3), AB116549 (Genotype-F3), AY090459 (Genotype-F1a), AY090458 (Genotype-4 
F1a).  5 
The accession number of F1b/RT sequences are the following: AY090459,  AY090458, EU670260,  6 
HM627320,  HM585194,  HM585200,  KJ843178,  JX079936,  KJ843177,  KJ810949,  7 
HM585197,  HM585192,  KJ843204,  KJ843200,  KJ843199,  KJ843197,  HM585193,  KJ843196, 8 
JN688703,  KJ843167,  KF414666,  AB116552, JN688699,  KJ843195,  KJ843168,  KJ843170,  9 
KJ843169,  AB116654,  HM585186,  HM590472,  KM233681,  HM590471,  HM590474,  10 
KJ843190,  KJ843174,  KJ843202,  KJ843194,  KJ843180,  KJ843181,  KJ843164,  KJ843203,  11 
KJ843201,  KJ843198,  KJ843179,  KJ843176,  KJ843163,  HE981182,  HE981183,  HE981185,  12 
KJ843171,  KJ810946,  KJ810944,  KJ810942,  KJ810939,  HM622135,  HM590473,  HM585195,  13 
HM585198,  HM585196,  HM585199. 14 
Genetic distances were calculated in the set of RT/HBsAg-sequences and BCP/Pre-Core/Core-15 
sequences using MEGA 6.0 based on Kimura-2 parameter (K2P) model [12,13]. 16 
 To avoid potential contaminations identical sequences amplified in the same run were excluded.  17 
Supplementary Methods III 18 
Ultra-deep pyrosequencing (UDPS) of HBV Reverse Transcriptase, HBsAg, Basal Core 19 
Promoter/Pre-Core/Core. 20 
The extent of genetic heterogeneity in RT, HBsAg, BCP/Pre-Core/Core was also investigated by 21 
UDPS (Roche 454-Junior). RT/HBsAg UDPS was available for 8/8 patients, and BCP/Pre-22 
Core/Core UDPS for 4/8 patients. 23 
The RT/HBsAg and BCP/Pre-Core/Core-sequences obtained by UDPS were used to define the 24 
intra-patient prevalence of mutations in each patient analyzed. Mutations were defined as aa 25 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
5 
 
variation from the HBV F1b reference sequence. Only mutations detected in > 4 reads in both 1 
forward and reverse primers were considered for the analysis.  2 
Overall, the mean ± standard deviation coverage per aminoacid position was 6,809±2,967 reads for 3 
RT/HBsAg, 6,841±1,682 reads for Pre-core, and 4,569±1,738 reads for Core. For BPC the 4 
variability was evaluated per each nucleotide position with a mean ± standard deviation coverage of 5 
6,238±1,207 reads.  6 
UDPS protocols for RT/HBsAg and BCP/Pre-Core/Core are reported below.  7 
Protocol for ultra-deep pyrosequencing (UDPS) of HBV Reverse Transcriptase/HBsAg.  8 
PCR-barcoded primers were designed to amplify four partially overlapping amplicons covering the 9 
full-length RT region, and the overlapping complete region of the HBsAg. In particular, four 10 
fragments of 424, 332, 384 and 427 nucleotides, encompassing the RT and HBsAg genomic region, 11 
were generated by nested PCR using barcoded-modified primers after a first amplification. Nested-12 
PCR was performed with the Fast Start HiFi PCR system (Roche Diagnostics, Mannheim, 13 
Germany) under the following conditions: 1 cycle of 94°C for 3 min, 30 cycles of 94°C for 30 s, 14 
60°C for 30 s, 72°C for 35sec, followed by a final extention at 72°C for 7 min. The amplified 15 
products were purified using Agencourt AMPure XP PCR purification beads (Beckman Coulter, 16 
Brea, CA) and quantified with the Quant-iT PicoGreen dsDNA Assay Kit (Life Technologies, 17 
Eugene, Oregon USA) by GloMax Multidetection System (Promega, Wisconsin USA). Equimolar 18 
pooled PCR products were clonally amplified on captured beads in water-oil emulsion 19 
microreactors (1.2 DNA-copies/beads). A total of 500,000 DNA-enriched beads were deposited in 20 
the GS Junior Titanium PicoTiterPlate device and pyrosequenced in both forward and reverse 21 
directions. The 200 nucleotide cycles were performed in a 10h sequencing run.  22 
Protocol for ultra-deep pyrosequencing (UDPS) of HBV Basal Core Promoter, Pre-Core, 23 
Core region. 24 
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PCR-barcoded primers were designed to amplify four partially overlapping amplicons covering the 1 
BCP/Pre-Core/Core genomic region. In particular, four fragments of 470, 503, 334 and 474 2 
nucleotides encompassing BCP/Pre-Core/Core genomic region were generated by Nested PCR.  3 
The 4 amplicons were performed with the Fast Start HiFi PCR system (Roche Diagnostics, 4 
Mannheim, Germany). For the first amplicon (470 nucleotides fragment) the following conditions 5 
were used: 1 cycle of 94°C for 3 min, 30 cycles of 94°C for 30 s, 56°C for 30 s, 72°C for 35sec, 6 
followed by a final extention at 72°C for 7 min. For the other three amplicons, the PCR conditions 7 
were superimposable, with the exception of the annealing temperature that was of 64°C, 55°C and 8 
55°C, respectively. 9 
The amplified products were purified using Agencourt AMPure XP PCR purification beads 10 
(Beckman Coulter, Brea, CA) and quantified with the Quant-iT PicoGreen dsDNA Assay Kit (Life 11 
Technologies, Eugene, Oregon USA) by GloMax Multidetection System (Promega, Wisconsin 12 
USA). Equimolar pooled PCR products were clonally amplified on captured beads in water-oil 13 
emulsion microreactors (1.2 DNA-copies/beads). A total of 500,000 DNA-enriched beads were 14 
deposited in the GS Junior Titanium PicoTiterPlate device and pyrosequenced in both forward and 15 
reverse directions. The 200 nucleotide cycles were performed in a 10h sequencing run.  16 
Bioinformatic Analysis of RT/HBsAg and BCP/Pre-Core/Core UDPS Sequences 17 
The UDPS sequences obtained after 454-pyrosequencing  were de-multiplexed and quantified using 18 
the standard flowgram format (SFF) tool by Roche. By an home-made pearl script calling for 19 
Blast algorithm, all reads were checked for homology with reference strains (>80%) and the 20 
orientation was discerned [1]. After this filtering, SHORAH package 0.5.1 [2] were used to correct 21 
sequences for homolymeric region associated errors, using as reference the sequences obtained 22 
from population sequencing. Subsequently the sequences were clustered, taking into account for 23 
reads redundancy and forward/reverse directions, using Exonerate 2.2.0 package [3] and aligned 24 
against the HBV F1b reference sequences  using Needleman–Wunsch algorithm (Emboss package) 25 
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[4, 5]. The final alignments were manually checked for insertion or deletion in homopolymeric 1 
region that would results in a frame shift. At each position the coverage and the amino acid variants 2 
were evaluated by a home-made pearl script. Phylogenetic analyses were performed to avoid any 3 
possible contamination or mixing among the pooled samples analyzed. 4 
Sensitivity of UDPS for detecting minor variants 5 
The frequency of errors resulting from amplification and deep sequencing was assessed using a 6 
plasmid containing the HBsAg gene as control. Mismatch nucleotide error rate was very low after 7 
sequencing correction (<0.006%). Furthermore, considering only the variants covered in both 8 
orientations in more than 4 reads, we never found mismatch in the control plasmid, thus only 9 
variants with these characteristic were considered reliable for the analyses.  10 
 11 
 12 
 13 
  14 
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